FastForward Innovations Ltd (LON:FFWD) has said its portfolio company EMMAC Life Sciences, in which it holds a 2.3% stake, has been selected as a supplier for an upcoming medical cannabis trial in France through its partnership with homoeopathic products maker Boiron.
In an announcement late on Tuesday afternoon, EMMAC said the trial, the first of its kind in France, will allow 3,000 patients access to medical cannabis as a treatment option for certain ailments including chronic pain, epilepsy, oncology and spasticity under tightly controlled conditions.
The company said the French Agency for the Safety of Medicines and Health Products (ANSM) has selected EMMAC’s 20/1 and 10/10 oral solutions as second-source treatments which will be available to patients and healthcare professionals as part of the two-year trial.
It added that the partnership will combine Boiron’s expertise in plant-based medicine with EMMAC’s “uniquely controlled European supply chain” to deliver pharmaceutical-grade cannabis medicines that “meet the strict requirements of product quality, safety and traceability”.
"We are proud to have been selected to be part of this important trial. Alongside Boiron, we are pleased to share our international experience to advance the industry's understanding of the benefits of medical cannabis”, EMMAC chief executive Antonio Costanzo said in a statement.
“The selection of our products by ANSM is testament to EMMAC's scientific knowledge and rigour, as well as our ability to provide products to the highest standards of compliance, safety and quality", he added.